# US 6,080,409 A · Immunostimulatory method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,080,409 A
- Document ID: US6080409A
- Status: Granted
- Kind: A
- Application number: 08/579,823
- Filed: 1995-12-28
- Granted: 2000-06-27
- Earliest claimed: 1995-12-28
- Assignees: Dendreon Corporation
- Inventors: Reiner Laus; Curtis Landon Ruegg; Hongyu Wu
- Web page: https://patentgrep.com/patent/US6080409A

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 39/001139: {Colony stimulating factors [CSF]}
- A61K 39/001193: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/4746: {p53}
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/71: for growth factors; for growth regulators
- C12N 9/16: acting on ester bonds (3.1)
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/6031: {Proteins}
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.

## Claims

### Claim 1

A method of inducing a T cell-mediated cellular immune response to a soluble peptide antigen in a mammalian subject, comprising
isolating antigen presenting cells (APCs) from the subject;
exposing said APCs in vitro to a conjugate of granulocyte macrophage stimulating factor (GM-CSF) covalently linked to the soluble peptide antigen under conditions effective to activate the responder proliferation activity of the APCs;
as evidenced by the ability of said APCs to stimulate proliferation of responder cells in vitro;
administering said activated APCs to the subject.

### Claim 2 (depends on 1)

The method according to claim 1, for use in treating a tumor, wherein the soluble peptide antigen is a tumor-specific antigen.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the conjugate further comprises, between said GM-CSF and said soluble peptide antigen, a linker peptide.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antigen presenting cell is an activated dendritic cell.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said conjugate further comprises a fusion protein produced by translation of a continuous nucleotide coding region.

### Claim 6 (depends on 2)

The method of claim 2, for use in treating prostate cancer, wherein the soluble antigen is prostatic acid phosphatase (PAP).

### Claim 7 (depends on 2)

The method of claim 2, for use in treating breast cancer, wherein the soluble antigen is the Her-2 antigen.